Cellect Biotechnology Ltd. Form 6-K Summary
Business Context and Reporting Period
This Form 6-K, filed on September 6, 2016, reports on the results of an Extraordinary General Meeting of Series 1 Option Holders held on September 4, 2016. The registrant, Cellect Biotechnology Ltd., is an Israeli company with principal executive offices in Kfar Saba. The filing addresses the Company's transition to a reporting regime under the U.S. Securities Exchange Act of 1934.
Financial Metrics
The filing text does not provide a clear value for revenue, profit, cash flow, margins, debt, or liquidity. This report focuses exclusively on corporate governance and regulatory status rather than financial performance.
Material Changes
The primary material event reported is the approval by Series 1 option holders of the Company's transition to U.S. reporting standards. This approval is a prerequisite for the subsequent vote by ordinary shareholders and American depository share holders scheduled for September 18, 2016.
Outlook and Management Commentary
Management indicates that the transition to the U.S. reporting regime is proceeding as planned following the option holder approval. The next critical step is the shareholder vote on September 18, 2016. No specific financial guidance, risk factors, or contingencies regarding operations were detailed in this specific filing.
Key Facts for Investor Verification
- Series 1 option holders approved the transition to U.S. reporting on September 4, 2016.
- Ordinary shareholders and ADS holders are scheduled to vote on the same matter on September 18, 2016.
- The Series 1 options are traded solely on the Tel Aviv Stock Exchange.
- This filing contains no financial performance data for the period.